UniProt O43781 · PDB · AlphaFold · Substrate: DYRKtide · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 100.0% | 0.0% | 91.48 | 0.563 |
| 2 | Defactinib | 87.7% | 12.3% | 92.68 | 0.450 |
| 3 | Palbociclib | 58.8% | 41.2% | 98.75 | 0.673 |
| 4 | Afatinib | 53.5% | 46.5% | 98.50 | 0.709 |
| 5 | Sunitinib | 47.9% | 52.1% | 91.73 | 0.524 |
| 6 | Avapritinib | 45.2% | 54.8% | 97.73 | 0.644 |
| 7 | Ponatinib | 41.2% | 58.8% | 78.23 | 0.534 |
| 8 | Gilteritinib | 40.9% | 59.1% | 88.97 | 0.506 |
| 9 | Osimertinib | 39.1% | 60.9% | 97.24 | 0.733 |
| 10 | Dacomitinib | 37.4% | 62.6% | 97.99 | 0.664 |
| 11 | Crizotinib | 36.5% | 63.5% | 91.39 | 0.581 |
| 12 | Selpercatinib | 32.6% | 67.4% | 96.72 | 0.635 |
| 13 | Neratinib | 31.7% | 68.3% | 93.18 | 0.597 |
| 14 | Gefitinib | 27.1% | 72.9% | 99.25 | 0.650 |
| 15 | Pacritinib | 25.1% | 74.9% | 88.64 | 0.452 |
| 16 | Midostaurin | 19.8% | 80.2% | 78.64 | 0.500 |
| 17 | Capivasertib | 18.1% | 81.9% | 96.48 | 0.644 |
| 18 | Brigatinib | 17.6% | 82.4% | 82.96 | 0.513 |
| 19 | Erlotinib | 17.4% | 82.6% | 99.75 | 0.695 |
| 20 | Darovasertib | 16.2% | 83.8% | 96.99 | 0.719 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.94
- Epithelial log2(TPM+1): 1.37
- Fold change: 1.57
- Status: Upregulated
High-confidence drugs
- Abemaciclib — inh 100.0% · KISS 37.42
- Defactinib — inh 87.7% · KISS 18.96
- Palbociclib — inh 58.8% · KISS 5.55
Selectivity landscape vs inhibition on DYRK3
Each point is one of the 92 approved drugs; color = inhibition % on DYRK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…